Discover how blarcamesine, a novel therapy for Alzheimer’s, shows promise in preventing cognitive decline and enhancing patient quality of life.

Simplistic explanations and convenient scapegoats belie the complexity of mass shootings.

Cognitive behavioral therapy for insomnia effectively treats chronic insomnia, promoting long-term sleep improvement through targeted behavioral strategies.

Moral injuries in health care professionals became an increasing focus during the COVID-19 pandemic, with all the obstacles, uncertainty, and risks of patient care.

"This can still happen anywhere. Not everything is lost."

More than 20 years later, what have we learned about PTSD, resiliency, and trauma?

Susan Noonan, MD, discusses emerging research on the potential role of lithium deficiency in Alzheimer disease.

Allen Frances, MD, introduces his new weekly series for Psychiatric Times: “AI Chatbots: The Good, the Bad, and the Ugly.”

Oregon's "Create Resilience" Youth Art Contest celebrates creativity in mental health, showcasing powerful youth submissions that inspire hope and connection.

It is time to redefine treatment resistance, a definition in which we emphasize comprehensive evaluations and personalized approaches for better patient outcomes.

An expert expresses concerns over NRx-100's "expanded access" for ketamine, questioning its safety claims and prioritizing market strategy over patient care.

This article explores the lasting impact of 9/11 on mental health, moral injury, and the role of first responders in crisis situations.

Frank A. Clark, MD, reflects on current state of our country.

Christina Ni, MD, explores the lasting effects of 9/11 on trauma survivors, emphasizing individualized care and the importance of support networks in healing.

September: the beginning of the season of change.

Takeda's oveporexton shows promising results in treating narcolepsy type 1, significantly improving symptoms and quality of life in clinical trials.

Christine Yu Moutier, MD, discusses suicide prevention strategies, highlighting risk factors and the importance of culturally competent care for vulnerable populations.

Today is World Suicide Prevention Day. Media training emerges as a vital tool for psychiatrists, enhancing suicide prevention efforts and combating misinformation in mental health.

New research reveals ART12.11, a cannabidiol:tetramethylpyrazine cocrystal, significantly enhances mood regulation, outperforming traditional cannabidiol in treating mood and anxiety disorders.

Explore the complexities of geriatric psychiatry, addressing mental health challenges in aging populations with expert insights and practical strategies.

Alto Neuroscience reveals EEG biomarkers effectively distinguish patients with schizophrenia, enhancing treatment precision and advancing psychiatric research.

What do you do when a patient, who is also a physician, disagrees? A psychiatrist navigates complex mental health challenges, rejecting a bipolar diagnosis while advocating for patient autonomy and addressing stigma in health care.

Tonmya, the first new FDA-approved fibromyalgia treatment in 15 years, shows promise in reducing pain and improving patient outcomes according to newly released data.

FDA approves Amneal Pharmaceuticals' new long-acting injectable risperidone for schizophrenia, enhancing treatment options and potentially patient adherence.